Comparative Study on the Duration and Efficacy of Various Botulinum Toxin Type A Injections for Reducing Masseteric Muscle Bite Force and Treating Facial Wrinkles
28
Issued Date
2024-01-01
Resource Type
ISSN
21938210
eISSN
21909172
Scopus ID
2-s2.0-85192478422
Journal Title
Dermatology and Therapy
Rights Holder(s)
SCOPUS
Bibliographic Citation
Dermatology and Therapy (2024)
Suggested Citation
Sirisuthivoranunt S., Wongdama S., Phumariyapong P., Nokdhes Y.N., Thongjaroensirikul P., Techapichetvanich T., Pettersson M., Ågren M., Wanitphakdeedecha R. Comparative Study on the Duration and Efficacy of Various Botulinum Toxin Type A Injections for Reducing Masseteric Muscle Bite Force and Treating Facial Wrinkles. Dermatology and Therapy (2024). doi:10.1007/s13555-024-01177-1 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/98355
Title
Comparative Study on the Duration and Efficacy of Various Botulinum Toxin Type A Injections for Reducing Masseteric Muscle Bite Force and Treating Facial Wrinkles
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Objective: Botulinum toxin serotype A (BoNT/A) is widely used for minimal invasive aesthetic treatments. Different brands of BoNT/A exhibit structural variations. The aim of this study was to compare the duration and efficacy of various BoNT/A brands available in Thailand for reducing bite force and treating wrinkles. Methods: Fifty participants were randomly assigned to one of five groups, with each group receiving a different BoNT/A brand, namely, incobotulinumtoxinA (IncoA), onabotulinumtoxinA (OnaA), abobotulinumtoxinA (AboA), letibotulinumtoxinA (LetiA), and prabotulinumtoxinA (PraboA). BoNT/A was administered to the masseter muscle and the upper face. Bite force was measured before injection and at 2, 4, 8, 12, 16, 20, and 24 weeks post-injection. Evaluation scores for wrinkle improvement were assessed after the treatment. Results: The most significant reduction in bite force occurred between 2 and 4 weeks post-injection. PraboA demonstrated the most substantial reduction in bite force, while IncoA had the least effect. However, the percentage of bite force reduction did not exhibit statistical significance between BoNT/A types. Additionally, the reduction in bite force for all BoNT/A types was reversed at 4 months post-injection. More than half of the participants experienced improvement beyond 16 weeks. Conclusions: The structural differences among BoNT/A brands did not significantly affect the longevity and efficacy of bite force reduction and wrinkle treatment. Trial Registration: ClinicalTrials.gov identifier: TCTR20211205001 (registered 4 Dec 2021).